Literature DB >> 19052045

Factors contributing to the time taken to consult with symptoms of lung cancer: a cross-sectional study.

S M Smith1, N C Campbell, U MacLeod, A J Lee, A Raja, S Wyke, S B Ziebland, E M Duff, L D Ritchie, M C Nicolson.   

Abstract

OBJECTIVES: To determine what factors are associated with the time people take to consult with symptoms of lung cancer, with a focus on those from rural and socially deprived areas.
METHODS: A cross-sectional quantitative interview survey was performed of 360 patients with newly diagnosed primary lung cancer in three Scottish hospitals (two in Glasgow, one in NE Scotland). Supplementary data were obtained from medical case notes. The main outcome measures were the number of days from (1) the date participant defined first symptom until date of presentation to a medical practitioner; and (2) the date of earliest symptom from a symptom checklist (derived from clinical guidelines) until date of presentation to a medical practitioner.
RESULTS: 179 participants (50%) had symptoms for more than 14 weeks before presenting to a medical practitioner (median 99 days; interquartile range 31-381). 270 participants (75%) had unrecognised symptoms of lung cancer. There were no significant differences in time taken to consult with symptoms of lung cancer between rural and/or deprived participants compared with urban and/or affluent participants. Factors independently associated with increased time before consulting about symptoms were living alone, a history of chronic obstructive pulmonary disease (COPD) and longer pack years of smoking. Haemoptysis, new onset of shortness of breath, cough and loss of appetite were significantly associated with earlier consulting, as were a history of chest infection and renal failure.
CONCLUSION: For many people with lung cancer, regardless of location and socioeconomic status, the time between symptom onset and consultation was long enough to plausibly affect prognosis. Long-term smokers, those with COPD and/or those living alone are at particular risk of taking longer to consult with symptoms of lung cancer and practitioners should be alert to this.

Entities:  

Mesh:

Year:  2008        PMID: 19052045     DOI: 10.1136/thx.2008.096560

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  41 in total

1.  Polypsychopharmacy.

Authors:  S Sturges; M Brown
Journal:  Bull Menninger Clin       Date:  1975-05

2.  Reducing the time before consulting with symptoms of lung cancer: a randomised controlled trial in primary care.

Authors:  Sarah Smith; Shona Fielding; Peter Murchie; Marie Johnston; Sally Wyke; Rachael Powell; Graham Devereux; Marianne Nicolson; Una Macleod; Phil Wilson; Lewis Ritchie; Amanda J Lee; Neil C Campbell
Journal:  Br J Gen Pract       Date:  2013-01       Impact factor: 5.386

3.  Association of smoking with tumor size at diagnosis in non-small cell lung cancer.

Authors:  Xing Chen; Ivan P Gorlov; Kelly W Merriman; Shih-Feng Weng; Millennia Foy; Gwendolyn Keener; Christopher I Amos; Margaret R Spitz; Marek Kimmel; Olga Y Gorlova
Journal:  Lung Cancer       Date:  2011-06-08       Impact factor: 5.705

Review 4.  Defining timeliness in care for patients with lung cancer: a scoping review.

Authors:  Adnan Ansar; Virginia Lewis; Christine Faye McDonald; Chaojie Liu; Muhammad Aziz Rahman
Journal:  BMJ Open       Date:  2022-04-07       Impact factor: 2.692

5.  Timeliness of care and prognosis in patients with lung cancer.

Authors:  F J Gonzalez-Barcala; J A Falagan; J M Garcia-Prim; L Valdes; J M Carreira; A Puga; P Martín-Lancharro; M T Garcia-Sanz; D Anton-Sanmartin; J C Canive-Gomez; A Pose-Reino; R Lopez-Lopez
Journal:  Ir J Med Sci       Date:  2013-10-04       Impact factor: 1.568

6.  Understanding diagnosis of lung cancer in primary care: qualitative synthesis of significant event audit reports.

Authors:  Elizabeth D Mitchell; Greg Rubin; Una Macleod
Journal:  Br J Gen Pract       Date:  2013-01       Impact factor: 5.386

7.  Developing a complex intervention to reduce time to presentation with symptoms of lung cancer.

Authors:  Sarah M Smith; Peter Murchie; Graham Devereux; Marie Johnston; Amanda J Lee; Una Macleod; Marianne C Nicolson; Rachael Powell; Lewis D Ritchie; Sally Wyke; Neil C Campbell
Journal:  Br J Gen Pract       Date:  2012-09       Impact factor: 5.386

Review 8.  Comorbid chronic diseases and cancer diagnosis: disease-specific effects and underlying mechanisms.

Authors:  Cristina Renzi; Aradhna Kaushal; Jon Emery; Willie Hamilton; Richard D Neal; Bernard Rachet; Greg Rubin; Hardeep Singh; Fiona M Walter; Niek J de Wit; Georgios Lyratzopoulos
Journal:  Nat Rev Clin Oncol       Date:  2019-07-26       Impact factor: 66.675

Review 9.  Socio-economic inequalities in stage at diagnosis, and in time intervals on the lung cancer pathway from first symptom to treatment: systematic review and meta-analysis.

Authors:  Lynne F Forrest; Sarah Sowden; Greg Rubin; Martin White; Jean Adams
Journal:  Thorax       Date:  2016-09-28       Impact factor: 9.139

10.  Genetic evidence linking lung cancer and COPD: a new perspective.

Authors:  Robert P Young; Raewyn J Hopkins; Gregory D Gamble; Carol Etzel; Randa El-Zein; James D Crapo
Journal:  Appl Clin Genet       Date:  2011-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.